Filing Flows › Health Care › Labcorp Holdings (LH)
Labcorp Holdings (LH) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 30, 2026 · Labcorp Holdings (LH) Q3 2026 earnings results →
Q3 2026 Revenue up 7% year over year to $3.8B · 7¢ of every $1 of revenue kept as net profit · operating margin 10.6%
Labcorp Holdings made $3.8B in Q3 2026 (+7% Y/Y). Operating margin 10.6%, net earnings $263M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 30, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.8B in Q3 2026, up 7% year over year and up 2% from the previous quarter.
Gross margin was 29.1%, up 0.3 points from Q3 2025. Operating profit was $0.40B, a 10.6% margin (down 0.6 points year over year). Of the extra revenue versus Q3 2025, 2% reached operating profit, below the 11% margin then. Operating expenses grew 12% against revenue growth of 7%. The fastest-growing cost line was Other operating costs (+25%). Net earnings were $0.26B, up 1% year over year. The effective tax rate was 19.8%.
Operating cash flow was $0.56B (up 46% year over year), 214% of net earnings. Non-cash charges added back $0.18B of depreciation and amortization and $0.03B of share-based compensation. Working capital and other items added $0.09B. After capital Expenditures ($0.15B), free cash flow as the company reports it was $0.41B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 30, 2026 | $3.8B | +7% | 10.6% | $263M | $564M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $3.7B | +6% | 12.1% | $299M | $446M |
| Q1 2026 | 10-Q | May 4, 2026 | $3.5B | +6% | 10.8% | $278M | $192M |
| Q4 2025 | 10-K | Feb 24, 2026 | $3.5B | +6% | 7.6% | $165M | $614M |
| Q3 2025 | 10-Q | Oct 31, 2025 | $3.6B | +9% | 11.1% | $262M | $387M |
| Q2 2025 | 10-Q | Aug 1, 2025 | $3.5B | +10% | 11.2% | $238M | $621M |
| Q1 2025 | 10-Q | Apr 29, 2025 | $3.3B | +5% | 9.7% | $213M | $18.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Labcorp Holdings
Labcorp ® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world. In addition, the Company provided support for more than 85% of the new drugs and therapeutic products approved in 2025 by the FDA.
In its own words, from its 10-K, filed Feb 24, 2026.
Labcorp Holdings against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +7% against the peers' median +15%. Operating margin: 10.6% against the peers' median 7.0%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
| VCYT Veracyte | Q3 2026 | $152M | +15% | 10.9% |
Source: Labcorp Holdings 10-Q on SEC EDGAR · CIK 920148 · Services-Medical Laboratories
Guidance and outlook
13F: who owns LH and who is buying
More on LH
- How Labcorp Holdings makes money: revenue by segment
- Labcorp Holdings next earnings date and what analysts expect
- Labcorp Holdings stock forecast, price target and fair value
- Who owns Labcorp Holdings stock: holders, funds and Congress trades
- Labcorp Holdings guidance and outlook
- Is Labcorp Holdings a takeover target? LBO and rumors
- Labcorp Holdings recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results